[{"id":"15523e72-2092-4615-84e9-c8dac7362a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07484087","created_at":"2026-03-28T01:36:33.328Z","updated_at":"2026-03-28T01:36:33.328Z","phase":"","brief_title":"Ablation Compare With Surgery for Early Breast Cancer","source_id_and_acronym":"NCT07484087","lead_sponsor":"Peking University People's Hospital","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + AR positive + ER positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + AR positive + ER positive"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2026-03-19"},{"id":"df568c08-818e-4e88-a7ec-38377deb4c56","acronym":"","url":"https://clinicaltrials.gov/study/NCT07162051","created_at":"2025-09-13T08:42:14.196Z","updated_at":"2025-09-13T08:42:14.196Z","phase":"Phase 2","brief_title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT07162051","lead_sponsor":"Xijing Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-09-09"},{"id":"e6296b14-457a-49ec-b305-921eba77b4de","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088588","created_at":"2025-08-02T14:24:39.476Z","updated_at":"2025-08-02T14:24:39.476Z","phase":"Phase 1","brief_title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07088588","lead_sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-07-28"},{"id":"f99e9a96-78aa-4611-a09e-0bb82a397f5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06967103","created_at":"2025-06-07T15:00:18.246Z","updated_at":"2025-06-07T15:00:18.246Z","phase":"Phase 2","brief_title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06967103","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 238","initiation":"Initiation: 05/20/2025","start_date":" 05/20/2025","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 05/30/2029","study_completion_date":" 05/30/2029","last_update_posted":"2025-05-13"},{"id":"bf338af6-7bdc-4263-a249-2470acc07fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06860529","created_at":"2025-06-07T14:59:59.699Z","updated_at":"2025-06-07T14:59:59.699Z","phase":"Phase 2","brief_title":"Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06860529","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 357","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-03-06"},{"id":"356e037f-a448-4ff1-b399-8d43d9152a11","acronym":"","url":"https://clinicaltrials.gov/study/NCT05946668","created_at":"2023-07-14T18:09:09.966Z","updated_at":"2025-02-25T12:38:41.091Z","phase":"","brief_title":"Evaluation of Vaginal Microbiome As a Biomarker for the Improvement of Vaginal Health in Women with Breast Cancer, ARISE Study","source_id_and_acronym":"NCT05946668","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-24"},{"id":"53a3393c-70b7-4bcc-a8e3-5120097c6768","acronym":"OVELIA","url":"https://clinicaltrials.gov/study/NCT04906395","created_at":"2021-05-28T13:52:36.773Z","updated_at":"2025-02-25T12:28:09.357Z","phase":"Phase 3","brief_title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","source_id_and_acronym":"NCT04906395 - OVELIA","lead_sponsor":"Tolmar Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-24"},{"id":"68ed3b37-b467-4c04-902f-70c0e053d74f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02945579","created_at":"2021-01-18T14:27:45.395Z","updated_at":"2025-02-25T12:26:33.859Z","phase":"","brief_title":"Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT02945579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/20/2017","start_date":" 01/20/2017","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"74157a34-d6de-4ba9-9962-025f2effcf7f","acronym":"ALPHABET","url":"https://clinicaltrials.gov/study/NCT05063786","created_at":"2021-10-01T11:54:26.039Z","updated_at":"2025-02-25T12:37:59.796Z","phase":"Phase 3","brief_title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","source_id_and_acronym":"NCT05063786 - ALPHABET","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" ER positive • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-24"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"e892208a-36f9-4d6f-a38c-e7cd64d31bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659136","created_at":"2021-01-18T17:57:27.537Z","updated_at":"2025-02-25T12:26:58.565Z","phase":"Phase 2","brief_title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","source_id_and_acronym":"NCT03659136","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2025-02-24"},{"id":"fe52e481-e906-4f7f-a53f-550a7128a15c","acronym":"EVANGELINE","url":"https://clinicaltrials.gov/study/NCT05607004","created_at":"2022-11-07T13:56:21.386Z","updated_at":"2025-02-25T12:38:26.751Z","phase":"Phase 2","brief_title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","source_id_and_acronym":"NCT05607004 - EVANGELINE","lead_sponsor":"Atossa Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/14/2023","start_date":" 02/14/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-24"},{"id":"06f9902f-3398-49ea-bdd4-ce2518db4d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886531","created_at":"2021-05-14T12:52:33.790Z","updated_at":"2025-02-25T13:49:09.000Z","phase":"Phase 2","brief_title":"Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","source_id_and_acronym":"NCT04886531","lead_sponsor":"Ruth O'Regan","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-21"},{"id":"21be25ed-db5c-4f88-af53-6dabef3b154a","acronym":"SUMIT-ELA","url":"https://clinicaltrials.gov/study/NCT05963997","created_at":"2023-07-27T17:09:07.832Z","updated_at":"2025-02-25T13:41:37.681Z","phase":"Phase 1/2","brief_title":"A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","source_id_and_acronym":"NCT05963997 - SUMIT-ELA","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 10/09/2023","start_date":" 10/09/2023","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-02-21"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"3f832c54-ae2b-45dd-b72a-df4624a79314","acronym":"SUMIT-BC","url":"https://clinicaltrials.gov/study/NCT05963984","created_at":"2023-07-27T17:09:07.566Z","updated_at":"2025-02-25T13:41:37.189Z","phase":"Phase 2","brief_title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","source_id_and_acronym":"NCT05963984 - SUMIT-BC","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"909260a0-1d22-47e9-9081-eb961f7d0511","acronym":"","url":"https://clinicaltrials.gov/study/NCT06184750","created_at":"2023-12-28T15:17:32.895Z","updated_at":"2025-02-25T13:42:00.077Z","phase":"Phase 2","brief_title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","source_id_and_acronym":"NCT06184750","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ADAR","pipe":"","alterations":" ","tags":["ADAR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/27/2024","start_date":" 09/27/2024","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-21"},{"id":"98d3d9bc-9e64-4b61-be85-59f415cfe1f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05573126","created_at":"2022-10-10T14:05:29.537Z","updated_at":"2025-02-25T13:41:17.825Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","source_id_and_acronym":"NCT05573126","lead_sponsor":"Ellipses Pharma","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-21"},{"id":"c28173c9-ac67-4f97-95aa-85bf990befb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052555","created_at":"2021-01-18T19:52:14.840Z","updated_at":"2025-02-25T13:39:55.670Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04052555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2025-02-21"},{"id":"54f667c3-3716-4279-a108-c5768e0f70d9","acronym":"REALNESS","url":"https://clinicaltrials.gov/study/NCT06676436","created_at":"2025-02-25T14:04:59.533Z","updated_at":"2025-02-25T14:04:59.533Z","phase":"","brief_title":"Observational Study on the Treatment of Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT06676436 - REALNESS","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR positive + HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/30/2024","start_date":" 11/30/2024","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-19"},{"id":"91477ff8-142f-4402-9532-82ad52403fb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03804944","created_at":"2021-01-18T18:48:24.995Z","updated_at":"2025-02-25T14:01:36.868Z","phase":"Phase 2","brief_title":"Converting HR+ Breast Cancer Into an Individualized Vaccine","source_id_and_acronym":"NCT03804944","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-19"},{"id":"be1e3182-1b8c-4aa1-8e6a-90c8411f7afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05996107","created_at":"2023-08-16T16:08:40.965Z","updated_at":"2025-02-25T14:03:44.386Z","phase":"Phase 1","brief_title":"Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT05996107","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"}]